A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: A pilot study

Journal of Gastrointestinal and Liver Diseases

Volumn 25, Issue 4, 2016, Pages 457-464

  Rahimpour, Shahab ^a   Nasiri Toosi, Mohsen ^a   Khalili, Hossein ^a   Daryani, Nasser Ebrahimi ^a   Taromlou, Mohammad Kazem Nouri ^a   Azizi, Zahra ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Liver function tests; Mayo risk score; Oral vancomycin; Placebo; Primary sclerosing cholangitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; URSODEOXYCHOLIC ACID; VANCOMYCIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CHOLAGOGUE; GAMMA-GLUTAMYLTRANSFERASE, HUMAN;

ABSENCE OF SIDE EFFECTS; ADULT; ANOREXIA; ARTICLE; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FATIGUE IMPACT SCALE; FEMALE; HUMAN; LUNG EMBOLISM; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALE; PILOT STUDY; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VISUAL ANALOG SCALE; AGED; BLOOD; CHOLANGITIS, SCLEROSING; COMBINATION DRUG THERAPY; IRAN; LIVER FUNCTION TEST; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; ALKALINE PHOSPHATASE; ANTI-BACTERIAL AGENTS; BIOMARKERS; BLOOD SEDIMENTATION; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; DRUG THERAPY, COMBINATION; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; IRAN; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PILOT PROJECTS; TIME FACTORS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID; VANCOMYCIN; YOUNG ADULT;

EID: 85006428035     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: 10.15403/jgld.2014.1121.254.rah     Document Type: Article

References (25)

1. Chandok N, Hirschfield GM. Management of primary sclerosing cholangitis: conventions and controversies. Can J Gastroenterol 2012; 26: 261.
2. Tabibian J, Weeding E, Jorgensen R, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis‐a pilot study. Aliment Pharmacol Ther 2013; 37: 604-612. doi: 10.1111/apt.12232
3. Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998; 27: 580-583.
4. Davies YK, Tsay CJ, Caccamo DV, Cox KM, Castillo RO, Cox KL. Successful treatment of recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral vancomycin. Case Rep Transplant 2013; 2013: 314292. doi: 10.1155/2013/314292
5. Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008; 47: 61-67. doi: 10.1097/MPG.0b013e31816fee95
6. Färkkilä M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo‐controlled trial. Hepatology 2004; 40: 1379-1386. doi: 10.1002/ hep.20457
7. Lindor KD. Ursodiol for primary sclerosing cholangitis Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-695. doi: 10.1056/NEJM199703063361003
8. Nayagam JS, Pereira SP, Devlin J, Harrison PM, Joshi D. Controversies in the management of primary sclerosing cholangitis. World J Hepatol 2016; 8: 265-272. doi: 10.4254/wjh.v8.i5.265
9. Tabibian JH, Talwalkar JA, Lindor KD. Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int 2013; 2013: 389537. doi: 10.1155/2013/389537
10. Shimizu M, Iwasaki H, Mase S, Yachie A. Successful treatment of primary sclerosing cholangitis with a steroid and a probiotic. Case Rep Gastroenterol 2012; 6: 249-253. doi: 10.1159/000338834
11. Rupp C, Bode K, Weiss KH, Rudolph G, et al. Microbiological Assessment of Bile and Corresponding Antibiotic Treatment: A Strobe-Compliant Observational Study of 1401 Endoscopic Retrograde Cholangiographies. Medicine 2016; 95: e2390. doi: 10.1097/MD.0000000000002390
12. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 1464-1472. doi: 10.1053/j. gastro.2005.08.017
13. Lindor KD, Kowdley KV, Luketic VA, et al. High‐dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-814. doi: 10.1002/hep.23082
14. Abarbanel DN, Seki SM, Davies Y, et al. Immunomodulatory effect of vancomycin on treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol 2013; 33: 397-406. doi: 10.1007/s10875-012-9801-1
15. Popper H. Cholestasis: the future of a past and present riddle. Hepatology 1981; 1: 187-191. doi: 10.1002/hep.1840010217
16. Reich A, Heisig M, Phan NQ, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 2012; 92: 497-501. doi: 10.2340/00015555-1265
17. Heidari M, Akbarfahimi M, Salehi M, Torabi-Nami M. Psychometric Properties of the Persian Version of Fatigue Impact Scale (FIS-P) in patients with Multiple Sclerosis. Iranian Rehabilitation Journal 2015; 13: 31-37.
18. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994; 18: S79-S83. doi: 10.1093/clinids/18. Supplement_1.S79
19. Aleksandrova EA, Avdeev VG, Burnevich EZ, Arion EA. Primary sclerosing cholangitis: present views of its pathogenesis, diagnosis and treatment. Ter Arkh 2012; 84: 86-90.
20. Gupta A, Bowlus C. Primary sclerosing cholangitis: etiopathogenesis and clinical management. Frontiers in bioscience (Elite edition) 2011;4:1683-705.
21. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013; 145: 521-536. doi: 10.1053/j.gastro.2013.06.052
22. Voigtländer T, Leuchs E, Vonberg RP, et al. Microbiological analysis of bile and its impact in critically ill patients with secondary sclerosing cholangitis. J Infect 2015; 70: 483-490. doi: 10.1016/j.jinf.2015.01.013
23. Rankin JG, Boden RW, Goulston SJ, Morrow W. The liver in ulcerative colitis treatment of pericholangitis with tetracycline. Lancet 1959; 274: 1110-1112. doi: 10.1016/S0140-6736(59)90098-4
24. Silveira MG, Torok NJ, Gossard AA, et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 2009; 104: 83-88. doi: 10.1038/ajg.2008.14
25. Boner AL, Peroni D, Bodini A, Delaini G, Piacentini G. Azithromycin may reduce cholestasis in primary sclerosing cholangitis: a case report and serendipitous observation. Int J Immunopathol Pharmacol 2007; 20: 847-849. doi: 10.1177/039463200702000423